NCT03017521
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: AKT, PI3K
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 19 Years and older (Adult, Senior)
Location of Metastases:
Additional Notes: Must have PI3K/AKT gene aberration
Exclusions:
https://ClinicalTrials.gov/show/NCT03017521